SARS-CoV-2 (COVID-19) Variants

Reagents against variants of SARS-CoV-2 accessory factors - antibodies and recombinant proteins against Alpha, Beta, Gamma variants 

In late 2020 new variants of SARS-CoV-2, began to appear in several different countries. Initially, the variants were named for the country in which they were first identified then a more recent system advanced by WHO, affords the variants a Greek letter name. Identified variants have since undergone further mutation and selection such that now it is important to specifically note the sequences of mutations within the specific variant.

For example, ProSci R&D has created antibodies specific to the P681H sequence first identified in the Alpha variant (Cat. No. 9359) and ProSci further offers antibodies and recombinant proteins within variants Alpha, Beta, Gamma, Epsilon, and Eta.

SARS-CoV-2 Alpha Variant Antibodies

ProductCat. No.ApplicationClonalitySpecies
SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike Antibody 9359 E, WB Polyclonal Rabbit
SARS-CoV-2 (COVID-19) Spike S1 Antibody 9083 E, WB, IF, IHC Polyclonal Rabbit
SARS-CoV-2 (COVID-19) Spike S1 Antibody [SP185] 10-351 E, IHC Monoclonal Rabbit
SARS-CoV-2 (COVID-19) Spike S1 Antibody [SP422] 10-350 E, IHC Monoclonal Rabbit
SARS-CoV-2 (COVID-19) Spike RBD Antibody 9087 E, WB, IF, IHC Polyclonal Rabbit
SARS-CoV-2 (COVID-19) Spike S1 Antibody (cleavage) 9091 E, WB, IF Polyclonal Rabbit


Non-synonymous mutations and deletions of Alpha Variants

GeneNucleotideAmino AcidProteinRelated ProSci AbsAb ImmunogenBiological Significance
Spike 21765-21770 deletion HV 69-70 deletion (S1-NT) Recurrent deletions in various lineages related to several RBD mutations
A23063T N501Y RBD 9087 Mutation site included An increase in the binding affinity of ACE2 receptor and enhance infectivity and virulence
C23604A P681H S1-CT 9359 Mutation site included Promote viral entry into human cells and transmission in animal models
21991-21993 Y144 deletion S1
C23271A A570D S1
C23709T T716I S2-NT
T24506G S982A S2'
G24914C D1118H S2'
ORF1ab C3267T T1001I NSP3/PL-PRO
C5388A A1708D NSP3/PL-PRO
T6954C I2230T NSP3/PL-PRO
11288-11296 deletion SGF 3675-3677 deletion NSP6
ORF8 C27972T Q27stop ORF8-NT A slight effect on virus replication in human cells with deletions
G28048T R52I ORF8 Incoming ORF8 Ab Mutation site included
A28111G Y73C ORF8 10-511 Mutation site included
N 28280 GAT-CTA D3L N-NT 35-579 Mutation site included
C28977T S235F N

[Edited from Rambaut et al, 2020]


Properties of Alpha Variant Antibodies against Other Variants

ProductCat. No.WTAlpha Variant | B.1.1.7 (U.K.)Beta Variant | B.1.135 (South Africa)Gamma Variant | P.1 (Brazil)Comments
SARS-CoV-2 (COVID-19) P681H Mutant Specific Spike Antibody 9359 - ++++ N/A N/A 9359 detects Alpha Variant but not WT
SARS-CoV-2 (COVID-19) Spike S1 Antibody 9083 ++++ ++++ ++++ - 9083 cannot detect Gamma Variant
SARS-CoV-2 (COVID-19) Spike S1 Antibody [SP185] 10-351 ++++ ++++ - - 10-351 cannot detect Beta and Gamma Variants
SARS-CoV-2 (COVID-19) Spike S1 Antibody [SP422] 10-350 ++++ ++++ ++ ++ 10-350 has a lower affinity for Beta and Gamma Variants
SARS-CoV-2 (COVID-19) Spike RBD Antibody 9087 ++++ +++ ++ + 9087 has a lower affinity for all variants
SARS-CoV-2 (COVID-19) Spike S1 Antibody (cleavage) 9091 ++++ ++ N/A N/A 9091 has a lower affinity for Alpha Variant


SARS-CoV-2 Variants Recombinant Proteins

* Click on Product to obtain fuller sequence information

ProductCat. No.SourceFusion TagSequence*
SARS-CoV-2 (COVID-19) Alpha S RBD RP 11-064 Mammalian Cells C-His N501Y
SARS-CoV-2 (COVID-19) Beta S RBD RP 11-065 Mammalian Cells C-His K417N, E484K, N501Y
SARS-CoV-2 (COVID-19) Gamma S RBD RP 11-066 Mammalian Cells C-His E484K, K417T, N501Y
SARS-CoV-2 (COVID-19) Alpha/Beta Spike Trimer 11-067 Mammalian Cells C-His E484K
SARS-CoV-2 (COVID-19) D614G Spike RP 92-748 Human Cells C-His D614G
SARS-CoV-2 (COVID-19) D614G Spike S1 RP 92-746 Human Cells C-His D614G
SARS CoV-2 spike protein in LMNG detergent 21-815 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS CoV-2 spike protein in DIBMA Glycerol 21-816 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS CoV-2 spike protein nanodisc complex 21-817 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) full-length Spike S1 Alpha (United Kingdom, Sept 2020) B.1.1.7 Variant RP 21-818 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) full-length Spike S1 Beta (South Africa, May 2020) B.1.351 Variant RP 21-819 HEK293 C-Terminal Rho1D4 Del 144; K417N; E484K; N501Y; A570D; D614G; P681H; T716I; S982A; D1118H; more…
SARS-CoV-2 (COVID-19) full-length Spike S1 Gamma (Brazil, Nov 2020) P.1 Variant RP 21-820 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) full-length Spike S1 Eta (United Kingdom, Dec 2020) B.1.525 Variant RP 21-821 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) full-length Spike S1 Epsilon (California) B.1.429 Variant RP 21-822 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) full-length Spike S1 Kappa (India, Dec 2020) B.1.617.1 Variant RP 21-823 HEK293 C-Terminal Rho1D4 AA 1-1273
SARS-CoV-2 (COVID-19) Spike RBD Alpha (United Kingdom, Sept 2020) B.1.1.7 Variant RP 21-824 HEK293 C-Terminal His Tag AA 319-537 (N501Y)
SARS-CoV-2 (COVID-19) Spike RBD Beta (South Africa, May 2020) B.1.351 Variant RP 21-825 HEK293 C-Terminal His Tag AA 319-537 (N501Y)
SARS-CoV-2 (COVID-19) Spike RBD Gamma (Brazil, Nov 2020) P.1 Variant RP 21-826 HEK293 C-Terminal His Tag AA 319-537 (K417T; E484K; N501Y)



References

  • Duchene, Sebastian, Leo Featherstone, Melina Haritopoulou-Sinanidou, Andrew Rambaut, Philippe Lemey, and Guy Baele. 2020. “Temporal Signal and the Phylodynamic Threshold of SARS-CoV-2.” Virus Evolution 6 (2): veaa061.
  • Gamage, Akshamal M., Kai Sen Tan, Wharton O. Y. Chan, Jing Liu, Chee Wah Tan, Yew Kwang Ong, Mark Thong, et al. 2020. “Infection of Human Nasal Epithelial Cells with SARS-CoV-2 and a 382-Nt Deletion Isolate Lacking ORF8 Reveals Similar Viral Kinetics and Host Transcriptional Profiles.” PLoS Pathogens 16 (12): e1009130.
  • Gu, Hongjing, Qi Chen, Guan Yang, Lei He, Hang Fan, Yong-Qiang Deng, Yanxiao Wang, et al. 2020. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (6511): 1603–7.
  • Hoffmann, Markus, Hannah Kleine-Weber, and Stefan Pöhlmann. 2020. “A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.” Molecular Cell 78 (4): 779–84.e5.
  • Kemp, S. A., D. A. Collier, R. Datir, S. Gayed, A. Jahun, M. Hosmillo, Iatm Ferreira, et al. 2020. “Neutralising Antibodies Drive Spike Mediated SARS-CoV-2 Evasion.” Infectious Diseases (except HIV/AIDS). medRxiv. https://doi.org/10.1101/2020.12.05.20241927.
  • McCarthy, Kevin R., Linda J. Rennick, Sham Nambulli, Lindsey R. Robinson-McCarthy, William G. Bain, Ghady Haidar, and W. Paul Duprex. 2020. “Natural Deletions in the SARS-CoV-2 Spike Glycoprotein Drive Antibody Escape.” Microbiology. bioRxiv.
  • Peacock, Thomas P., Daniel H. Goldhill, Jie Zhou, Laury Baillon, Rebecca Frise, Olivia C. Swann, Ruthiran Kugathasan, et al. 2020. “The Furin Cleavage Site of SARS-CoV-2 Spike Protein Is a Key Determinant for Transmission due to Enhanced Replication in Airway Cells.” Cold Spring Harbor Laboratory. https://doi.org/10.1101/2020.09.30.318311.
  • Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam S. Dingens, Mary Jane Navarro, et al. 2020. “Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.” Cell 182 (5): 1295–1310.e20.
  • Zhu, Yunkai, Fei Feng, Gaowei Hu, Yuyan Wang, Yin Yu, Yuanfei Zhu, Wei Xu, et al. 2020. “The S1/S2 Boundary of SARS-CoV-2 Spike Protein Modulates Cell Entry Pathways and Transmission.” Cold Spring Harbor Laboratory. https://doi.org/10.1101/2020.08.25.266775.